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The association of p53 codon 72 polymorphism with cancer has been investigated by several scientiﬁc groups with
controversial results. In the present study, we examined the genotypic frequency of this polymorphism in 54 patients with
advanced lung cancer and 99 normal controls from the geographical region of Greece. Sputum and bronchial washing samples
from each patient were assayed for the presence of human papillomavirus. Codon 72 heterozygous (Arg/Pro) patients were
also analysed for loss of heterozygosity at the TP53 locus, in order to determine the lost p53 allele (Arg or Pro). p53 Arg/Arg
genotype was signiﬁcantly increased in lung cancer patients compared to normal controls (50% vs 24.2%, P50.002). Human
papillomavirus was detected only in two patients (3.7%). Loss of heterozygosity at the TP53 locus was found in 14 out of 27
Arg/Pro patients (51.85%). The Pro allele was lost in 11 cases (78.6%), while the Arg allele was lost in three (21.4%). Our
results suggest that p53 codon 72 Arg homozygosity is associated with advanced lung cancer, and that the Arg allele is
preferentially retained in patients heterozygous for this polymorphism. On the other hand, human papillomavirus infection
does not seem to play an important role in lung carcinogenesis.
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Lung cancer is the most common cause of cancer-related deaths in
Greece, accounting for 574 deaths per million people per year
(Jemal et al, 2002). Radical treatment depends primarily on early
detection, since patients with advanced and metastatic disease have
5-year survival rates less than 5% (Hirsch et al, 2001). Identiﬁca-
tion of early molecular events in lung carcinogenesis, such as ras
gene mutations or p53 inactivation, could have a major impact
on early detection of this disease (Viallet and Minna, 1990).
Human papillomavirus (HPV) has been implicated in the devel-
opment of several human cancers, including cervical, oesophageal,
skin, and laryngeal cancer (zur Hausen, 1996). Among the proteins
encoded in the HPV genome, early protein E6 binds p53 and
promotes its degradation through the ubiquitin-dependent proteo-
lytic pathway (Scheffner et al, 1990, 1993). HPV DNA is detected
in less than 10% of lung cancer patients (Kinoshita et al, 1995;
Bohlmeyer et al, 1998; Clavel et al, 2000), suggesting that HPV
does not play an important role in the development of lung cancer.
The human p53 tumour suppressor gene is located on chromo-
some 17p13 and encodes a 53-kDa nuclear phosphoprotein, which
plays a central role in many cellular processes, such as DNA repair
and apoptosis (Levine, 1997). Allelic loss at the TP53 locus is
observed in more than 50% of human cancers, disclosing aberra-
tions, like missense point mutations, in the retained allele
(Hollstein et al, 1991). The p53 gene is mutated in more than
50% of lung cancer cases (Takahashi et al, 1991).
p53 exists in two principal polymorphic forms that have either
arginine (p53Arg) or proline (p53Pro) at codon 72 (Matlashewski
et al, 1987). It has been proposed that p53Arg protein is more
susceptible to inactivation through the E6-ubiquitin pathway
than the p53Pro isoform, and that p53 Arg/Arg homozygosity
is associated with increased risk of developing HPV-associated
cervical cancer (Storey et al, 1998). Similar studies on cervical
and other human cancers have produced contradictory results.
Several groups conﬁrmed the original ﬁnding (Makni et al,
2000; Zehbe et al, 2001), some have shown that the association
between p53 Arg/Arg genotype and cancer is unrelated to HPV
(Andersson et al, 2001), while others failed to ﬁnd an association
between p53Arg and cancer (Hamel et al, 2000; Tenti et al,
2000). In lung cancer, several studies found no correlation with
p53 codon 72 polymorphism (Birgander et al, 1995; Pierce et al,
2000), while others have found an association with the Pro allele
(Kawajiri et al, 1993; Wang et al, 1999; Fan et al, 2000).
However, in tumours with loss of heterozygosity (LOH) at the
TP53 locus, the Pro allele is preferentially deleted in germline
Arg/Pro heterozygotes (Brooks et al, 2000; Kawaguchi et al,
2000; Furihata et al, 2002).
In this study we examined the genotypic frequency of p53
codon 72 polymorphism and the presence of HPV infection in
54 patients with advanced lung cancer, compared to a healthy
control population, in order to identify their association with
lung carcinogenesis. Furthermore, using microsatellite analysis,
we investigated the frequency of LOH at the TP53 locus, in
patients heterozygous for the codon 72 polymorphism, in order
to determine possible preferential retention of either Arg or
Pro allele.
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Patients and controls
Fifty-four Greek Caucasian patients with advanced lung cancer
(Stages IIIb and IV) were recruited during the diagnostic workup
for lung cancer in the Department of Pulmonary Medicine,
University Clinic of Sotiria Hospital (Athens, Greece). Cancer
staging was performed with CT scan and ﬁberoptic bronchoscopy.
Mean age at diagnosis was 66.4+8.3 years, with men accounting
for 85.2% of cases. Patients were heavy smokers with an average
of 64.6+31.4 pack-years (Table 1). Histologically, cancer cases
comprised 23 adenocarcinomas, 24 squamous cell carcinomas, six
small cell lung carcinomas and one large cell carcinoma. Cytologi-
cal specimens of sputum and bronchial washing were obtained
from each patient and stored at 7808C until DNA extraction.
Matched peripheral blood samples were collected in tubes contain-
ing EDTA and stored at 48C, to serve as source of genomic DNA.
Ninety-nine Greek Caucasian healthy individuals served as the
control group. They exhibited similar age, sex and smoking expo-
sure distribution with patients (Table 1) and derived from the
same geographical area. Peripheral blood samples were obtained
from each individual and stored at 48C for further use.
The Ethics Committees of the University of Crete and the
University Clinic of Sotiria Hospital approved this study and all
participants gave written informed consent.
DNA extraction
Sputum, bronchial washing and peripheral blood samples from
patients as well as peripheral blood samples from controls were
lysed with 400 mM Tris-HCl pH 8.0, 150 mM NaCl, 60 mM EDTA
and 1% SDS, adding 50 mg Proteinase K and incubated for 5 h at
658C.
DNA from all specimens was extracted with phenol/chloroform
and chloroform, precipitated with absolute ethanol, washed with
70% ethanol and resuspended in 100 ml double distilled water.
The presence of ampliﬁable DNA was tested in a PCR reaction
using a set of primers for the b2-microglobulin (b2-m) gene (Table
2).
p53 codon 72 polymorphism analysis
For the determination of the polymorphism at codon 72 of the p53
gene, an allele-speciﬁc PCR assay was used (Storey et al, 1998), that
selectively detects either the Arg or Pro p53 allele (Table 2). A total
of 100 ng of peripheral blood DNA from patients and controls was
ampliﬁed in a PCR reaction containing 16 buffer (20 mM Tris-
HCl pH 8.4 and 50 mM KCl), 1.6 mM MgCl2, 200 mM of each
dNTP, 200 nM of each primer and 0.024 U ml
71 Taq polymerase
(Gibco BRL, Invitrogen Corporation) in a ﬁnal volume of 25 ml.
Detection of the two polymorphic variants was carried out in
two different tubes. Ampliﬁcation was performed as follows: initial
denaturation at 948C for 3 min, ampliﬁcation for 35 cycles at 948C
for 30 s, 608C for the Arg allele and 548C for the Pro allele for 30 s
and 728C for 30 s, followed by a ﬁnal elongation step at 728C for
5 min. PCR products were 141 bp for the Arg allele and 177 bp for
the Pro allele. Heterozygous specimens had both PCR products,
whereas homozygous samples exhibited only one of the two
products. In each PCR reaction two blank samples were employed
as negative controls, to ensure that no contaminants were intro-
duced. PCR products were analysed by electrophoresis in a 2%
agarose gel, stained with ethidium bromide and photographed on
a UV light transilluminator. Procedures were repeated twice and
results were 100% reproducible.
This analysis was also conducted in bronchial washing speci-
mens from heterozygous (Arg/Pro) patients with LOH at the
TP53 locus. Faint bands in the position of the lost allele were inter-
preted as DNA contamination from normal lung cells.
LOH analysis at the TP53 locus
For the determination of LOH at the TP53 locus, the TP53 micro-
satellite marker set was used (Table 2). A total of 100 ng of
peripheral blood and bronchial washing DNA from each heterozy-
gous (Arg/Pro) patient was ampliﬁed in a PCR reaction containing
16 buffer, 2.66 mM MgCl2, 500 mM of each dNTP, 100 nM of each
primer and 0.04 U ml
71 Taq polymerase in a ﬁnal volume of
25 ml. Ampliﬁcation was carried out as follows: initial heating at
948C for 3 min, ampliﬁcation for 30 cycles at 948C for 30 s,
558C for 30 s and 728C for 30 s and ﬁnal elongation at 728C for
10 min. PCR products were analysed by electrophoresis in a 10%
polyacrylamide gel and silver stained. LOH was scored when a
signiﬁcant reduction (450%) in the intensity of one allele was
observed. Most LOH cases exhibited faint bands in the position
of deleted alleles, which was interpreted as contamination with
normal DNA. Analysis in LOH positive cases was repeated at least
twice and results were highly reproducible.
HPV detection and typing
For the detection of HPV genome, the general primers GP5 and
GP6 were used (Table 2). A total of 100 ng of sputum and bron-
chial washing DNA from each patient was ampliﬁed in a PCR
reaction containing 16 buffer, 1.6 mM MgCl2, 200 mM of each
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 1 Descriptive characteristics of the study population
Lung cancer patients Normal controls
Cases, n 54 99
Sex, n (%)
Male 46 (85.2%) 84 (84.8%)
Female 8 (14.8%) 15 (15.2%)
Age, mean+s.d., years 66.4+8.3 65.8+9.7
Pack-years, mean+s.d. 64.6+31.4 63.2+29.3
Table 2 Primer sequences and length of PCR products
Primer PCR product
pair Sequence 5'–3' size (bp)
Arg TCC CCC TTG CCG TCC CAA 141
CTG GTG CAG GGG CCA CGC
Pro GCC AGA GGC TGC TCC CCC 177
CGT GCA AGT CAC AGA CTT
TP53 ATC TAC AGT CCC CCT TGC CG 297
GCA ACT GAC CGT GCA AGT CA
b2-m TCC AAC ATC AAC ATC TTG GT 123
TCC CCC AAA TTC TAA GCA GA
GP5 TTT GTT ACT GTG GTA GAT AC 139–145
GP6 GAA AAA TAA ACT GTA AAT CA
HPV 18 AAA CTA ACT AAC ACT GGG TTA TAC A 143
ATG GCA CTG GCC TCT ATA GT
HPV 16 CTG CAA GCA ACA GTT ACT GCG ACG 315
CAT ACA TCG ACC GGT CCA CC
HPV 11 TGT GTG GCG AGA CAA CTT TCC CTT 236
TGG TTA TTT AGT TTT ATG AAG CGT GCC TTT CC
HPV 33 AAC AGT TAA AAA ACC TTT AAA 171
AGT TTC TCT ACG TCG GGA CCT C
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71 Taq polymerase in
a ﬁnal volume of 25 ml. The mixture was heated at 948C for 3 min
and samples were ampliﬁed for 40 cycles at 948C for 30 s, 528C for
30 s and 728C for 30 s, followed by elongation at 728C for 5 min.
PCR products were expected to be 139–145 bp, depending on
HPV type (Snijders et al, 1990).
HPV typing of all HPV-positive samples was carried out using
multiplex PCR. Speciﬁc pairs of primers were used to simulta-
neously amplify regions of HPV types 11, 16, 18 and 33 in the
same reaction tube, giving different lengths of ampliﬁed DNA.
Each HPV-positive sputum or bronchial washing sample was
ampliﬁed in a PCR reaction containing 16 buffer, 2.66 mM
MgCl2, 0.05% W-1, 533 mM of each dNTP, 166 nM of each primer
and 0.04 U ml
71 Taq polymerase in a ﬁnal volume of 15 ml.
Ampliﬁcation parameters were: initial heating at 948C for 2 min
and 30 s, 10 cycles of ampliﬁcation at 948C for 30 s, 528C for
40 s and 728C for 45 s, 30 cycles of ampliﬁcation at 928C for
30 s, 488C for 40 s and 728C for 45 s, and ﬁnal extension at
728C for 10 min. To establish type speciﬁcity of primer-directed
ampliﬁcation, each set of primers was tested with template plasmid
DNA of the four HPV types (11, 16, 18 and 33). PCR products
were analysed by electrophoresis in a 2% agarose gel, stained with
ethidium bromide and photographed on a UV light transillumina-
tor. Primer sequences and length of PCR products are shown in
Table 2.
Statistical analysis
Statistical analysis was performed using the w
2, Fisher’s Exact and
Mann–Whitney U tests, with the package SPSS 10.0 for Windows.
Statistical signiﬁcance was regarded at P-value 50.05.
RESULTS
p53 Arg is associated with advanced lung cancer
Peripheral blood DNA from 54 patients with advanced lung cancer
was analysed, in order to determine the distribution of p53 codon
72 polymorphism. In order to detect any discrepancy in the
frequency of this polymorphism among cancer patients and the
general population, peripheral blood specimens from 99 healthy
individuals were subjected to the same PCR-based genotyping
assay.
Distribution of the three genotypes, Arg/Arg, Arg/Pro and Pro/
Pro, was 50%, 50% and 0% in lung cancer patients, and 24.2%,
64.7% and 11.1% in healthy controls respectively (Table 3). Based
on the above results, the relative frequency of each allele was 0.75
for Arg and 0.25 for Pro in cancer patients, and 0.565 for Arg and
0.435 for Pro in normal controls, indicating a statistically signiﬁ-
cant difference (w
2=7.99, P50.005, odds ratio (OR)=2.36, 95%
conﬁdence intervals (CI)=1.24–4.50). Further analysis revealed
that the frequency of Arg/Arg genotype was considerably higher
in patients than in controls (w
2=10.43, P50.002, OR=3.13, 95%
CI=1.46–6.73). This association was also observed separately in
adenocarcinomas (w
2=9.20, P50.003, OR=4.06, 95% CI=1.44–
11.62) and squamous cell carcinomas (w
2=6.19, P50.02,
OR=3.13, 95% CI=1.13–8.69), but not in small cell lung carcino-
mas (Fisher’s Exact test, P=0.56) or in large cell carcinomas
(Fisher’s Exact test, P=0.25).
Interestingly, both study groups (patients and controls) showed
a deviation from the Hardy–Weinberg equilibrium due to excess
of heterozygotes (Controls: w
2
HW=9.86, f=1, P50.002; Patients:
w
2
HW=6.00, f=1, P50.02).
Patients were then stratiﬁed according to age, sex, histological
classiﬁcation and smoking exposure (in pack-years). A signiﬁcant
association of Arg/Arg adenocarcinomas with lower number of
pack-years was observed, compared to Arg/Pro adenocarcinomas
(30+8.5 vs 65+8.5) (Mann–Whitney U test, Z=74.073,
P50.001). No other statistically signiﬁcant difference was found
between the codon 72 polymorphism and the other variables exam-
ined.
p53 Pro is preferentially deleted in Arg/Pro germline
heterozygotes
Lung cancer patients heterozygous for the codon 72 polymorphism
(27 in total) were examined for LOH at the TP53 locus. Matched
DNA samples from peripheral blood and bronchial washing were
analysed, using the TP53 microsatellite marker (Figure 1B). A total
of 14 of 27 Arg/Pro patients (51.85%) exhibited LOH (Figure 1A).
In order to identify the deleted p53 allele, the 14 bronchial washing
samples with LOH were analysed for the codon 72 polymorphism
(Figure 1C, D). The Arg allele was preferentially retained, as it was
lost only in three (21.4%) cases, whereas the Pro allele was lost in
11 (78.6%) cases (Table 4).
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Table 3 Distribution of p53 codon 72 polymorphism among normal
controls and various histological types of lung cancer
Arg/Arg (%) Arg/Pro (%) Pro/Pro (%) Total
Normal controls 24 (24.2) 64 (64.7) 11 (11.1) 99
Lung cancer type
Adenocarcinomas 13 (56.5) 10 (43.5) 0 (0) 23
Squamous cell carcinomas 12 (50.0) 12 (50.0) 0 (0) 24
Small cell carcinomas 1 (16.7) 5 (83.3) 0 (0) 6
Large cell carcinomas 1 (100) 0 (0) 0 (0) 1
Total 27 (50) 27 (50) 0 (0) 54
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Figure 1 (A) Representative examples of specimens exhibiting LOH at
the TP53 locus. N; DNA from peripheral blood lymphocytes. W; DNA ex-
tracted from bronchial washing. Arrows indicate the missing allele. The
upper row indicates patient code number. (B) Location of the TP53 micro-
satellite marker at chromosome 17p13. (C) PCR ampliﬁcation of p53 co-
don 72 Arg allele (141 bp). N; DNA from peripheral blood lymphocytes.
W; DNA extracted from bronchial washing. B; blank sample. M; 123 bp
molecular weight marker. The upper row indicates patient code number.
(D) PCR ampliﬁcation of p53 codon 72 Pro allele (177 bp). N; DNA from
peripheral blood lymphocytes. W; DNA extracted from bronchial washing.
B; blank sample. M; 123 bp molecular weight marker. The upper row indi-
cates patient code number.
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In order to determine the frequency of HPV in advanced lung
cancer, and to ﬁnd a possible association with p53 codon 72 poly-
morphism, matched biological specimens, from the upper
(sputum) and lower (bronchial washing) respiratory system of each
patient, were analysed for the presence of HPV, using the general
primers GP5 and GP6. HPV DNA was detected in two cases
(3.7%), a squamous cell carcinoma and a large cell carcinoma.
However, in the patient with squamous cell carcinoma, HPV was
detected only in sputum and not in bronchial washing (Figure
2A). Multiplex PCR revealed that both patients harboured the
high-risk HPV-18 type (Figure 2B). Although the Arg/Arg genotype
of p53 codon 72 polymorphism was observed in both HPV-positive
cases, this ﬁnding was not statistically signiﬁcant (Fisher’s Exact
test, P=0.25).
DISCUSSION
This population-based case-control study was conducted to exam-
ine the prevalence of p53 codon 72 polymorphism in a Greek
Caucasian population of advanced lung cancer patients and normal
controls. The Arg/Arg homozygous genotype was statistically high-
er in patients than in controls (50% vs 24.2%, P50.002). This
ﬁnding is in accordance with the original publication on HPV-
associated cervical cancer (Storey et al, 1998), with previous studies
by our group in cervical (Dokianakis and Spandidos, 2000), breast
(Papadakis et al, 2000), skin (Dokianakis et al, 2000), laryngeal
(Sourvinos et al, 2001) and bladder cancer (Soulitzis et al, 2002),
as well as with another Greek study in cervical intra-epithelial
neoplasia and cervical cancer (Agorastos et al, 2000).
Both study groups showed deviation from the Hardy-Weinberg
equilibrium (Controls: w
2
HW=9.86, P50.002; Patients: w
2
HW=6.00,
P50.02). Several studies exhibit this deviation in the control (Jin
et al, 1995; Makni et al, 2000) or patients group (Kawajiri et al,
1993; Tandle et al, 2001). This cannot be attributed to methodolo-
gical problems. The technique used to type this polymorphism (i.e.
allele speciﬁc PCR), has a tendency to under-estimate heterozygotes
(if an allele speciﬁc PCR product is not found, the specimen is
characterised as homozygous for the other allele). On the contrary,
the method that uses analysis with restriction enzymes, has a
tendency to over-estimate heterozygotes (due to incomplete diges-
tion of PCR products from the restriction enzyme). Therefore,
regarding the cancer population, the Hardy-Weinberg equilibrium
deviation could be attributed to selection bias due to the disease
itself. As for the control group, it could be attributed to non-
random selection, since enlisted subjects had speciﬁc characteristics
(age, sex and smoking exposure) matching those of the cancer
group. Nevertheless, from a statistical point of view, this Hardy-
Weinberg equilibrium deviation does not affect our ﬁndings.
Calculating the theoretical genotype frequencies for both controls
and patients, the increase of Arg/Arg genotype in patients is statis-
tically signiﬁcant (w
2=9.08, P50.003, OR=2.82, CI=1.35–5.94).
These values are only slightly lower than the ones calculated with
the observed genotypic frequencies (w
2=10.43, P50.002,
OR=3.13, CI=1.46–6.73).
The frequency of Pro allele in the control group is 43.5%. It has
been proposed that geographical location and ethnicity play an
important role in p53 allele frequencies (Beckman et al, 1994).
Distribution of Pro allele in Caucasian populations varies from
24% (Finland) (Beckman et al, 1994) to 53% (India) (Tandle et
al, 2001). Therefore, the Pro allele frequency of this study is not
high, taking into account the geographical location of Greece and
the genetic characteristics of our population. Furthermore, it is
similar to that found by another Greek study (48%) (Agorastos
et al, 2000) and by a Turkish (a proximate population) study
(39%) (Toruner et al, 2001).
Several scientiﬁc groups have drawn opposite conclusions, asso-
ciating p53Pro with lung carcinogenesis. This discrepancy could be
attributed to various reasons. In some studies cancer population
comprised patients eligible for surgical treatment (Stages I and
II) excluding patients with more advanced tumours (Fan et al,
2000), whereas all of our cases were inoperable lung cancers (Stages
IIIb and IV). Additionally, in studies involving advanced tumours,
statistical analysis did not reveal any association of p53Pro with
lung carcinogenesis (Wang et al, 1999). Moreover, variations in
protocols among laboratories, or poor selection of the control
group (Makni et al, 2000), could also explain the above mentioned
discrepancies. However, it seems that the main reason is ethnic
background. Populations across the earth exhibit signiﬁcant differ-
ences in the frequency of p53 codon 72 polymorphism, which can
be attributed to natural selection through ecological adaptation to
ultra-violet radiation (Beckman et al, 1994). Most studies that
associate p53Pro with lung cancer have been conducted in South-
east Asia (China, Taiwan or Japan), where another p53
polymorphism (a 16 bp duplication in intron 3) is almost absent
(frequency 51.5%). This 16 bp duplication, combined with the
Pro/Pro codon 72 genotype, offers protection against lung cancer.
Therefore, the low frequency of the protective 16 bp duplication in
these populations would make it easier to demonstrate an associa-
tion between p53Pro and cancer (Birgander et al, 1995).
Statistical analysis revealed that patients with Arg/Arg adenocar-
cinoma have lower pack-years of smoking history than those with
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Table 4 LOH at the TP53 locus in lung cancer specimens heterozygous
for the codon 72 polymorphism
Lost allele
p53 LOH Arg Pro
Adenocarcinomas 5/10 1/5 4/5
Squamous cell carcinomas 7/12 2/7 5/7
Small cell carcinomas 2/5 0/2 2/2
Total 14/27 3/14 11/14
A
B
M       B      53w   53s
bp
145
123
bp
143
123
22   HeLa    N       B        M
Figure 2 (A) Detection of HPV by PCR ampliﬁcation using the general
primers G5 and G6 (145 bp). 53w; bronchial washing. 53s; sputum. B; blank
sample. M; 123 bp molecular weight marker. The band at 123 bp corre-
sponds to the PCR product of b2-m gene, which was used to establish
the presence of ampliﬁable DNA. (B) Detection of HPV-18 by PCR am-
pliﬁcation (143 bp). 22; patient sample positive for HPV-18. HeLa; positive
control from HeLa cells. N; negative control. B; blank sample. M; 123 bp
molecular weight marker. The band at 123 bp corresponds to the PCR
product of b2-m gene, which was used to establish the presence of ampliﬁ-
able DNA.
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suggests that, as p53Arg confers susceptibility to lung carcinogen-
esis, lower dose of the carcinogen (tobacco) is required for
tumour development. Larger studies, including phase I (CYPs)
and phase II (GSTs and NATs) detoxiﬁcation enzymes, are needed
to verify this preliminary result.
Several functional assays demonstrate that the two polymorphic
variants of p53 have different biochemical and biological character-
istics (Storey et al, 1998; Thomas et al, 1999; Marin et al, 2000).
Codon 72 lies within a proline-rich domain of p53 required for
growth suppression (Walker and Levine, 1996) and apoptosis
(Sakamuro et al, 1997). It comprises ﬁve PxxP SH3 (SRC-homol-
ogy-3) binding motifs, one of which is lost when proline is
replaced with arginine. This substitution could account for the
difference that these two p53 variants exhibit in E6-mediated
degradation, transcription activation and induction of apoptosis,
and could explain the implication of codon 72 polymorphism in
carcinogenesis.
Of the 14 heterozygous (Arg/Pro) specimens with LOH at the
TP53 locus, 11 (78%) retained the Arg allele, while only three
(22%) retained the Pro allele. Preferential deletion of p53Pro has
also been described in HPV-associated oesophageal cancer (Kawa-
guchi et al, 2000), in squamous cell carcinoma of the vulva,
regardless of HPV infection (Brooks et al, 2000) and in transitional
cell carcinoma of the urinary tract (Furihata et al, 2002). The Arg
isoform of p53 codon 72 enhances certain p53 mutants to form
stable complexes with p73, blocking the apoptotic ability of p73
(Marin et al, 2000). Therefore, p53 mutants carrying the Arg allele
can lead to decreased activation of p53 target genes through inac-
tivation of p73 (Tada et al, 2001). Thus, there is a strong bias to
mutate and retain the Arg allele in tumours arising in Arg/Pro
germline heterozygotes.
HPV was detected in two (3.7%) lung cancer patients, a squa-
mous cell carcinoma and a large cell carcinoma. The low
frequency of HPV infection is consistent with previous studies
performed in lung cancer (Kinoshita et al, 1995; Bohlmeyer et al,
1998; Clavel et al, 2000), suggesting that HPV is not an important
factor in lung tumorigenesis. However, it is possible that the effect
of HPV infection can only be estimated when other important
carcinogenic factors, such as tobacco exposure, are not present
(Cheng et al, 2001). Typing assay revealed that both cases
harboured HPV-18. The high prevalence of this oncogenic HPV
type in the Greek population could be attributed to ethnic varia-
tions (Dokianakis et al, 1999). In the case of squamous cell
carcinoma, HPV DNA was detected only in sputum and not in
bronchial washing. This could mean either that HPV infection
was important solely as an early event in carcinogenesis and persis-
tence of viral DNA was not necessary for cancer progression
(Brooks et al, 2000), or that sputum was contaminated with cells
from the upper respiratory tract or the oral cavity, infected with
HPV. Both cases carried the Arg/Arg codon 72 genotype. Neverthe-
less, due to the low frequency of HPV infection, the association of
p53Arg with lung carcinogenesis was not related to HPV.
In conclusion, our data associate p53Arg with advanced lung
cancer and support the observation, that the Arg allele is preferen-
tially retained in Arg/Pro germline heterozygotes. Nonetheless,
additional population-based and functional studies are needed in
order to elucidate the role of p53 codon 72 polymorphism in lung
cancer development.
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